GlassScriptPhysician profile
Colin T Rabach
NPI 1699444687
$3,526.61
in general payments reported to CMS, 2019-2025
24 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $898 · 2024: $948 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $669.80 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $652.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.40 | 2022-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $221.68 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $207.45 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $196.60 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $167.48 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Exact Sciences Corporation | $164.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $159.99 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $142.84 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Amgen INC. | $138.66 | 2024-2025 | Otezla, Repatha, Repatha |
| Lundbeck LLC | $90.27 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $88.54 | 2023 | Spravato |
| Kowa Pharmaceuticals America, INC. | $70.89 | 2022-2023 | Seglentis, Livalo |
| Astellas Pharma US INC | $67.58 | 2024-2025 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45.54 | 2025 | |
| Pulmonx Corporation | $39.57 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Mylan Specialty L.P. | $36.06 | 2022-2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $33.48 | 2023-2024 | Voquezna |
| Inspire Medical Systems, INC. | $28.22 | 2023 | Inspire |
| Sumitomo Pharma America, INC. | $21.06 | 2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $19.50 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $16.88 | 2024 | Ingrezza |
| Horizon Therapeutics Plc | $15.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Rabach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.